UK PbR tariff "may cut costs without jeopardising care"
This article was originally published in Clinica
Payment by results, the UK's fixed-tariff case-mix-based payment system, "may have achieved" reductions in unit costs without detrimental impact on the quality of care. So suggests research into the impact of PbR based on "changes in key outcome variables measuring volume, cost and quality of care", during the years 2003-04 and 2005-06.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.